Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
CONCLUSIONS: Switching from TDF to TAF decreased the levels of renal and bone biomarkers, such as urinary L-FABP and NTx, but increased low density lipoprotein-cholesterol levels. Future studies should evaluate if these biomarkers, such as urinary L-FABP and NTx, truly detect serious adverse drug reactions early.PMID:34044856 | DOI:10.1186/s12981-021-00354-y
Source: AIDS Research and Therapy - Category: Infectious Diseases Authors: Mahoko Ikeda Yoshitaka Wakabayashi Koh Okamoto Shintaro Yanagimoto Shu Okugawa Kyoji Moriya Source Type: research
More News: Cholesterol | Drugs & Pharmacology | HIV AIDS | Infectious Diseases | Liver | Proteinuria | Study | Urology & Nephrology | Viread